FDA approves Tecentriq in combination with Cotellic and Zelboraf for patients with advanced skin cancer

Summary: The Food and Drug Administration (FDA) announced the approval of a new combination of three different drugs for the treatment of patients with BRAF V600 mutation-positive advanced melanoma. The new regimen combines an immunotherapy, Tecentriq (atezolizumab), with two targeted therapies, Cotellic (cobimetinib) and Zelboraf (vemurafenib).

Dr. Dan's Takeaway: Adding Tecentriq to the combination of two approved targeted therapies extended survival from 10.6 months to 15.1 months in patients with advanced melanoma with a BRAF mutation. This is the first approval of these three types of drugs used in combination, but others will soon follow.

Resources:

https://www.curetoday.com/view/cures-clinical-trial-corner-july-2020

Deskside with Dr. Dan

“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

- Dan Platt, M.D.
Chief Medical Officer